[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369663-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369663-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","rare-variants-modulating-phenotype-in-nf1-carriers-scientific-report","Rare variants modulating phenotype in NF1 carriers - scientific report","","Rare genetic disorder neurofibromatosis type 1 (NF1) shows highly variable phenotypes. The study tests whether additional rare variants in other genes modulate NF1 outcomes beyond NF1 variants alone. Exome-based analysis of 32 NF1 patients links solid cancers with a higher burden of cancer-driver variants, particularly DNA repair genes. Validation in 217 UK Biobank NF1 carriers shows enrichment of P/LP/VUS DNA repair variants in tumor patients, alongside ancillary traits such as cognitive impairment, macrocephaly, and connective defects.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/rare-variants-modulating-phenotype-in-nf1-carriers-scientific-report/369663/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/rare-variants-modulating-phenotype-in-nf1-carriers-scientific-report/369663.png","ImageObject",300,407,{"name":42,"@type":43},"Đào","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the study address about NF1 phenotypic variability?","Question",{"text":63,"@type":64},"The study examines whether additional rare variants in other genes, alongside NF1 variants, help explain the wide phenotypic variability seen in NF1 carriers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the researchers test the relationship between secondary variants and cancer?",{"text":68,"@type":64},"They analyzed exome sequencing data from 32 NF1 patients and compared variant burdens between those with solid cancers and those without, then validated findings in 217 NF1 carriers from UK Biobank.",{"name":70,"@type":61,"acceptedAnswer":71},"Which gene category showed significant enrichment in NF1 patients with tumors?",{"text":72,"@type":64},"Pathogenic/likely pathogenic and other clinically significant variants were enriched in DNA repair genes among NF1 patients with tumors.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369663,1790409191,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374402968488,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nRare variants modulating phenotype in NF1 carriers  \nElena Pasquinelli1,2, Giulia Casamassima1,2, Giulia Brunelli1,2, Omaima Belakhdar1,2, Samantha Minetto1,2, Salvatore Grosso3, Roberto Canitano4, Stefania Marsili5,  \nIgnazio Martellucci5, SalvadoraTindara Miano5, Roberto Petrioli5, Margherita Baldassarri1,2,6, Romina D’Aurizio7, Chiara Fallerini1,2,6 & Alessandra Renieri1,2,6􀀍  \nNeurofibromatosis type 1 (NF1) is a rare genetic disorder with highly variable phenotypes, ranging from psychosocial challenges and congenital malformations to benign tumors and even aggressive cancers. We hypothesize that this variability stems from additional rare variants in other genes, in addition to NF1 variants. The analysis of 32 NF1 patients revealed that those with solid cancers carried a higher average of cancer driver variants especially in DNA repair genes compared to those without (p \u003C 0.05). An extended validation study using 217 NF1 carriers (71 cancer and 146 controls) from UK biobank confirmed significant enrichment of pathogenic (P), likely pathogenic (LP) and uncertain significant (VUS) variants in DNA repair genes, in NF1 patients with tumors (FDR ≤0.05) . Furthermore, P/LP variants in other genes are shown in those patients with NF1 ancillary traits such as cognitive impairments, macrocephaly, and connective defects. This study provides novel evidence suggesting that additional genetic variants in other genes may contribute to the phenotypic variability observed in NF1, indicating that rare secondary mutational events could influence specific manifestations, adding complexity to its variable expressivity.  \nNeurofibromatosis type 1 (NF1) is one of the most pleiotropic genetic disorders, predisposing individuals to various dysfunctions, ranging from psychosocial issues, congenital malformations to tumors1,2. Tumors can be benign, often involving the central and peripheral nervous systems, or malignant, particularly in solid organs2. Among solid tumors, breast cancer is one of the most recognized in association with NF1, with specific prevention included in surveillance guidelines1,2.  \nThe role of genetic background is well established in many solid cancers, including breast cancer3. For instance, polygenic risk scores (PRSs) have been proposed to enhance the efficiency of cancer screening programs, extending their application to new age groups and diverse cancer types, such as breast, prostate, colorectal, pancreatic, ovarian, kidney, lung, and testicular cancers3. However, authors note that the absolute number of cancers in PRS-defined high-risk quantiles remains too low to justify screening, highlighting the importance of rare variants3.  \nThe impact of rare causative variants on NF1 expression is well documented, particularly in genomic microdeletions encompassing the NF1 gene. For example, the increased lifetime risk of malignant peripheral nerve sheath tumors is attributed to the loss of the contiguous SUZ12 gene4. However, the contribution of other rare variants (P/LP), outside the context of microdeletion syndromes, remains unexplored. In this work using an exome sequencing approach, we hypothesize that the wide phenotypic variability observed in families segregating the same NF1 variant is due to additional rare causative variants in other genes, supporting anoligogenic model. Our study aimed to explore genotype-phenotype correlations, considering the diverse clinical presentations observed in this NF1 mutated cohort. Some individuals exhibited hallmark NF1-related features, such as café-au-lait spots, neurofibromas, Lisch nodules, or skeletal anomalies, while others presented with clinical complications, including various solid tumors. To address this, we conducted a detailed analysis to investigate whether specific NF1 mutations or additional rare variants in other genes might correlate with distinct phenotypic expressions.  \n1Medical Genet","cbCaihMJ9TcPdjF9","https://ap.wps.com/l/cbCaihMJ9TcPdjF9","pdf",2760847,11,"English","# Results\n## Description of the patient cohort","[{\"question\":\"What question does the study address about NF1 phenotypic variability?\",\"answer\":\"The study examines whether additional rare variants in other genes, alongside NF1 variants, help explain the wide phenotypic variability seen in NF1 carriers.\"},{\"question\":\"How did the researchers test the relationship between secondary variants and cancer?\",\"answer\":\"They analyzed exome sequencing data from 32 NF1 patients and compared variant burdens between those with solid cancers and those without, then validated findings in 217 NF1 carriers from UK Biobank.\"},{\"question\":\"Which gene category showed significant enrichment in NF1 patients with tumors?\",\"answer\":\"Pathogenic/likely pathogenic and other clinically significant variants were enriched in DNA repair genes among NF1 patients with tumors.\"}]","Rare variants modulating phenotype in NF1 carriers - scientific report | PDF",1790183983,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e545b426674db7089e63af09964c2eb.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aaffd94242147058712630200b04ed53.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a58dc8648b847cdd4ced8f1e36783b2e.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2d77069bfe0b7868450937f3c4cb2a0a.webp",980,1287]